GSK (GSK) announced the approval of Exdensur by Japan’s Ministry of Health, Labour and Welfare, MHLW, as a treatment for bronchial asthma and CRSwNP. The MHLW approval was based on data from the SWIFT and ANCHOR phase III trials, which demonstrated the sustained efficacy of a twice-yearly dose of depemokimab versus placebo, both plus standard of care. In SWIFT-1 and SWIFT-2, treatment with depemokimab resulted in significant reductions in asthma exacerbations. Additionally, ANCHOR-1 and ANCHOR-2 showed significant improvements in nasal polyp size and nasal obstruction, two key measures of disease severity. Results from the SWIFT trials showed treatment with depemokimab resulted in a significant 58% and 48% reduction in the rate of annualised asthma exacerbations over 52 weeks from SWIFT-1 and SWIFT-2, respectively. Across these trials, depemokimab was well-tolerated, with patients experiencing a similar rate and severity of side effects as those receiving placebo.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Kennedy scales back number of vaccines recommended for children, NYT says
- GSK announces China’s NMPA approved Nucala as add-on maintenance treatment
- Trump Weekly: Furniture tariffs delayed, drugmakers hike prices
- Midday Fly By: Nvidia said to see strong H200 demand in China
- Pfizer (PFE) Tops List as Drugmakers Plan Price Hike on 350 Medications